

08 Sep 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi's MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 September 2024, including: [Johnson & Johnson](#) interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep [Sanofi](#)'s MS plans alive; WCLC preview; and [Mankind Pharma Ltd.](#) sets eyes on 5x growth.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J Interested In 'Differentiated' Obesity Assets](#)" - Scrip, 4 Sep, 2024.)

(Also see "[ESC: Kerendia Hits In Heart Failure, But Usage Unclear](#)" - Scrip, 1 Sep, 2024.)

(Also see "[Strong HERCULES Data Keep Sanofi's MS Plans Alive](#)" - Scrip, 2 Sep, 2024.)

(Also see "[WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention](#)" - Scrip, 2 Sep, 2024.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Fast And Furious – Leqvio Licensed, Bharat Serums In Bag, Mankind Sets Eyes On 5X Growth](#)" - Scrip, 3 Sep, 2024.)

[Click here to explore this interactive content online](#) ✨